Thomas Schinecker, CEO of Swiss pharma firm Roche, has dismissed fears that the company's sales targets would be threatened ...

Roche’s U.S. biotech subsidiary Genentech has wiped its website of past diversity reports as the company’s diversity and ...

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

A $30,000 scholarship programme will be launched alongside internship opportunities for science graduates as Roche Bermuda ...

Roche (RHHBY) announced that the Food and Drug Administration has approved a New Drug Application for an Evrysdi tablet for people living with ...

Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.

The market for Roche Holding AG's ( VTX:ROG ) shares didn't move much after it posted weak earnings recently. We ...

Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...

UBS upgraded Roche (RHHBY) to Buy from Neutral with a price target of CHF 338, up from CHF 300. The company offers sustainable growth with ...

An update from Roche Bobois SAS ( ($FR:RBO) ) is now available. Roche Bobois has reported its voting rights information as of January 31, 2025, ...

The FDA on Wednesday approved the industry’s first-ever tablet treatment for spinal muscular atrophy— Roche ’s SMN2 splicing ...

Boston, USA-based Newleos Therapeutics, a neuroscience company co-founded by Longwood Fund and seasoned leaders in CNS drug ...